Diseases Research Consortium (IRDiRC), as their newest member, to further advance their common goal to change the pace at which new therapies for rare diseases can be discovered and brought to patients. Millions of people worldwide are affected by rare diseases and 95 percent of those diseases do not have an approved therapy.
Recursion combines the best elements of automated biology and artificial intelligence to create a highly scalable drug discovery platform that is capable of finding new drugs and new ways to use old drugs, while simultaneously working on many diseases in parallel. The company has focused specifically on rare genetic disease treatments, and have identified two new therapies that will likely move to Investigational New Drug (IND) status this year, with more than a dozen additional therapies in the pipeline. The boldly stated corporate goal is 100 treatments by 2025.
“It is a natural fit for Recursion to be aligned with IRDiRC as we both have a passion for improving the lives of people with rare diseases,” said Chris Gibson, CEO of Recursion Pharmaceuticals. “We are confident the work we are doing can propel the discovery process for rare disease treatments, and we hope through our work and the work of our partners at IRDiRC, we can fundamentally shift the curve to get more therapies to more patients sooner.”
IRDiRC teams up researchers and organizations investing in rare diseases research to collaborate, pool expertise, and leverage resources in order to be efficient and streamline processes. IRDiRC is focused on improving the efficiency and effectiveness of rare diseases research, diagnosis, and treatment to accelerate medical breakthroughs for people affected by rare diseases.
In a statement from IRDiRC: “We warmly welcome Recursion Pharmaceuticals as a new member. We fully support them in fulfilling their challenging goal to discover 100 treatments for rare diseases by the year 2025. This goal is perfectly aligned with IRDiRC’s objectives for therapeutic development and will help us progress to the ultimate goal of benefitting rare disease patients worldwide.”
Recursion is a digital biology company industrializing drug discovery. Recursion does this by combining automation, artificial intelligence, machine learning, and in vivo validation capabilities with a highly cross-functional team to discover novel medicines and expand our collective understanding of biology. Recursion’s rich, relatable database of 4 petabytes of biological images generated in-house on the company’s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. Recursion is proudly headquartered in Salt Lake City. Learn more at www.recursionpharma.com or connect on www.recursionpharma.com, or connect on Twitter, Facebook, and LinkedIn.